Association of the innate immunity and inflammation pathway with advanced prostate cancer risk - PubMed (original) (raw)

Association of the innate immunity and inflammation pathway with advanced prostate cancer risk

Rémi Kazma et al. PLoS One. 2012.

Abstract

Prostate cancer is the most frequent and second most lethal cancer in men in the United States. Innate immunity and inflammation may increase the risk of prostate cancer. To determine the role of innate immunity and inflammation in advanced prostate cancer, we investigated the association of 320 single nucleotide polymorphisms, located in 46 genes involved in this pathway, with disease risk using 494 cases with advanced disease and 536 controls from Cleveland, Ohio. Taken together, the whole pathway was associated with advanced prostate cancer risk (P = 0.02). Two sub-pathways (intracellular antiviral molecules and extracellular pattern recognition) and four genes in these sub-pathways (TLR1, TLR6, OAS1, and OAS2) were nominally associated with advanced prostate cancer risk and harbor several SNPs nominally associated with advanced prostate cancer risk. Our results suggest that the innate immunity and inflammation pathway may play a modest role in the etiology of advanced prostate cancer through multiple small effects.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300. - PubMed
    1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867. - PMC - PubMed
    1. de Visser KE, Coussens LM (2005) The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 54: 1143–1152. - PMC - PubMed
    1. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24–37. - PubMed
    1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources